Clinical trial · no report yet · Phase 2
CheckMate 650
A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)
- NCT02985957 ↗
- Completed
- Bristol-Myers Squibb
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 4 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 2 Trial of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Prostate Cancer
- Interventions
- Nivolumab; Ipilimumab; Cabazitaxel; Prednisone
- Arms
- Cohort A (Arm A) · Experimental
- Cohort B (Arm B) · Experimental
- Cohort C (Arm C) · Experimental
- Cohort D (Arm D1) · Experimental
- Cohort D (Arm D2) · Experimental
- Cohort D (Arm D3) · Experimental
- Cohort D (Arm D4) · Experimental
- Enrollment
- 351
- Primary outcomes
- Objective Response Rate (ORR) Cohorts B and C Per BICR
- Objective Response Rate (ORR) Cohort D
- Radiographic Progression Free Survival (rPFS) for Cohorts B and C Per BICR
- Radiographic Progression-Free Survival (rPFS) for Cohort D
- Sponsor
- Bristol-Myers Squibb
- Start
- Mar 26, 2017
- Primary completion
- Apr 5, 2022
- Results posted
- Yes
- Registry record
- NCT02985957 · updated Dec 22, 2025
Publications
linked from the registry- Sharma P, Pachynski RK, Narayan V, Flechon A, Gravis G, Galsky MD, Mahammedi H, Patnaik A, Subudhi SK, Ciprotti M, Simsek B, Saci A, Hu Y, Han GC, Fizazi K. Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial. Cancer Cell. 2020 Oct 12;38(4):489-499.e3. doi: 10.1016/j.ccell.2020.08.007. Epub 2020 Sep 10. PubMed 32916128